Transforming growth factor-β and breast cancer risk in women with mammary epithelial hyperplasia

被引:105
作者
Gobbi, H
Dupont, WD
Simpson, JF
Plummer, WD
Schuyler, PA
Olson, SJ
Arteaga, CL
Page, DL
机构
[1] Vanderbilt Univ, Med Ctr, Sch Med, Dept Prevent Med, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Med Ctr, Sch Med, Dept Pathol, Nashville, TN 37232 USA
[3] Univ Fed Minas Gerais, Sch Med, Dept Anat Pathol, Belo Horizonte, MG, Brazil
[4] Vanderbilt Univ, Med Ctr, Sch Med, Dept Med, Nashville, TN 37232 USA
[5] Vanderbilt Univ, Med Ctr, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA
关键词
D O I
10.1093/jnci/91.24.2096
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Transforming growth factors-beta (TGF-beta s) regulate mammary epitheIiaI cell division. Loss of expression of TGF-beta receptor II (TGF-beta-RII) is related to cell proliferation and tumor progression. Breast epithelial hyperplastic lesions lacking atypia (EHLA) are associated with a mild elevation in breast cancer risk, We investigated the expression of TGF-beta-RII in EHLA and the risk of subsequent invasive breast cancer. Methods: We conducted a nested case-control study of women with biopsy-confirmed EHLA who did not have a history of breast cancer or atypical hyperplasia of the breast. Case patients (n = 54) who subsequently developed invasive breast cancer were matched with control patients (n = 115) who did not. Formalin-fixed, paraffin-embedded sections of breast biopsy specimens of all 169 patients with EHLA were studied by immunohistochemical analysis with antibodies against TGF-beta-RII, All P values are two-sided. Results: Women with breast EHLA and 25%-75% TGF-beta-RII-positive cells or less than 25% TGF-beta-RII-positive cells had odds ratios of invasive breast cancer of 1.98 (95% confidence interval [CI] = 0.95-4.1) or 3.41 (95% CI = 1.2-10.0), respectively (P for trend = .008). These risks are calculated with respect to women with EHLA that had greater than 75% TGF-beta-RII expression. Women with a heterogeneous pattern of TGF-beta-RII expression in their normal breast lobular units and either greater than 75%, 25%-75%, or less than 25% positive cells in their EHLA had odds ratios for breast cancer risk of 0.742 (95% CI = 0.3-1.8), 2.85 (95% CI = 1.1-7.1), or 3.55 (95% CI = 1.0-10.0), respectively (P for trend =.003). These risks are relative to women with a homogeneous pattern of expression in their normal lobular units and greater than 75% positive cells in their EHLA. Conclusion: This study indicates that loss of TGF-beta-RII expression in epithelial cells of EHLA is associated with increased risk of invasive breast cancer.
引用
收藏
页码:2096 / 2101
页数:6
相关论文
共 52 条
  • [1] ASSOCIATION OF P53 PROTEIN EXPRESSION WITH TUMOR-CELL PROLIFERATION RATE AND CLINICAL OUTCOME IN NODE-NEGATIVE BREAST-CANCER
    ALLRED, DC
    CLARK, GM
    ELLEDGE, R
    FUQUA, SAW
    BROWN, RW
    CHAMNESS, GC
    OSBORNE, CK
    MCGUIRE, WL
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (03) : 200 - 206
  • [2] Biomarkers in benign breast disease: Risk factors for breast cancer
    Allred, DC
    Hilsenbeck, SG
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (17) : 1247 - 1248
  • [3] Expression of a dominant negative type II TGF-β receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development
    Amendt, C
    Schirmacher, P
    Weber, H
    Blessing, M
    [J]. ONCOGENE, 1998, 17 (01) : 25 - 34
  • [4] The multifunctional role of transforming growth factor (TGF)-beta s on mammary epithelial cell biology
    Arteaga, CL
    Dugger, TC
    Hurd, SD
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1996, 38 (01) : 49 - 56
  • [5] ARTEAGA CL, 1988, CANCER RES, V48, P3898
  • [6] ANTI-TRANSFORMING GROWTH-FACTOR (TGF)-BETA ANTIBODIES INHIBIT BREAST-CANCER CELL TUMORIGENICITY AND INCREASE MOUSE SPLEEN NATURAL-KILLER-CELL ACTIVITY - IMPLICATIONS FOR A POSSIBLE ROLE OF TUMOR-CELL HOST TGF-BETA INTERACTIONS IN HUMAN BREAST-CANCER PROGRESSION
    ARTEAGA, CL
    HURD, SD
    WINNIER, AR
    JOHNSON, MD
    FENDLY, BM
    FORBES, JT
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) : 2569 - 2576
  • [7] Brattain Michael G., 1996, Current Opinion in Oncology, V8, P49, DOI 10.1097/00001622-199601000-00009
  • [8] Breslow NE, 1980, STAT METHODS CANC RE, V1, DOI DOI 10.1097/00002030-199912240-00009
  • [9] Breslow NE, 1987, STAT METHODS CANC RE, VII
  • [10] REDUCED SURFACE EXPRESSION OF TRANSFORMING GROWTH-FACTOR-BETA RECEPTOR-TYPE-II IN MITOGEN-ACTIVATED T-CELLS FROM SEZARY PATIENTS
    CAPOCASALE, RJ
    LAMB, RJ
    VONDERHEID, EC
    FOX, FE
    ROOK, AH
    NOWELL, PC
    MOOREN, JS
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (12) : 5501 - 5505